NATERA INC
NASDAQ: NTRA (Natera, Inc.)
Last update: 21 hours ago193.03
-9.97 (-4.91%)
| Previous Close | 203.00 |
| Open | 203.35 |
| Volume | 2,867,522 |
| Avg. Volume (3M) | 1,210,995 |
| Market Cap | 27,358,382,080 |
| Price / Sales | 12.05 |
| Price / Book | 16.82 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | -10.36% |
| Operating Margin (TTM) | -15.78% |
| Diluted EPS (TTM) | -1.47 |
| Quarterly Revenue Growth (YOY) | 36.50% |
| Total Debt/Equity (MRQ) | 15.78% |
| Current Ratio (MRQ) | 3.87 |
| Operating Cash Flow (TTM) | 153.12 M |
| Levered Free Cash Flow (TTM) | 120.93 M |
| Return on Assets (TTM) | -8.87% |
| Return on Equity (TTM) | -18.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Natera, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 3.0 |
| Average | 1.10 |
|
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 3.24% |
| % Held by Institutions | 96.37% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 260.00 (Evercore ISI Group, 34.69%) | Buy |
| Median | 253.50 (31.33%) | |
| Low | 215.00 (Wells Fargo, 11.38%) | Hold |
| Average | 245.50 (27.18%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 207.79 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 03 Mar 2026 | 250.00 (29.51%) | Buy | 207.04 |
| Baird | 27 Feb 2026 | 257.00 (33.14%) | Buy | 208.04 |
| Evercore ISI Group | 27 Feb 2026 | 260.00 (34.69%) | Buy | 208.04 |
| Wells Fargo | 27 Feb 2026 | 215.00 (11.38%) | Hold | 208.04 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MOSHKEVICH SOLOMON | - | 203.21 | -3,000 | -609,630 |
| RABINOWITZ DANIEL | - | 203.21 | -8,400 | -1,706,964 |
| RABINOWITZ MATTHEW | - | - | 0 | 0 |
| Aggregate Net Quantity | -11,400 | |||
| Aggregate Net Value ($) | -2,316,594 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 203.21 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MOSHKEVICH SOLOMON | Officer | 01 Apr 2026 | Automatic sell (-) | 3,000 | 203.21 | 609,630 |
| RABINOWITZ DANIEL | Officer | 01 Apr 2026 | Automatic sell (-) | 8,400 | 203.21 | 1,706,964 |
| RABINOWITZ MATTHEW | Officer | 31 Mar 2026 | Option execute | 41,708 | - | - |
| Date | Type | Details |
|---|---|---|
| 06 Feb 2026 | Announcement | Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes |
| 02 Feb 2026 | Announcement | Natera Submits Signatera™ CDx PMA to FDA |
| 28 Jan 2026 | Announcement | Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation |
| 26 Jan 2026 | Announcement | Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care |
| 21 Jan 2026 | Announcement | Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer |
| 20 Jan 2026 | Announcement | Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting |
| 13 Jan 2026 | Announcement | Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling |
| 12 Jan 2026 | Announcement | Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |